Sort by
Substantiation of the stages of interventions in patients with multifocal atherosclerosis with combined lesions of coronary arteries and lower extremity arteries

Objective. To study the features of staged interventions in patients with combined lesions of coronary arteries and arteries of the lower extremities. Materials and Methods. The results of surgical treatment of 26 patients with combined lesions of coronary arteries and lower extremity arteries for the period from 2016 to 2023, the first stage of which was myocardial revascularization, were analyzed, and the data of 22 patients who underwent revascularization of the lower extremity arteries before 2016 were retrospectively analyzed. The operations were performed without cardiopulmonary bypass. Venous and arterial graphs were used. Results. The postoperative period was uneventful in 35 (73%) patients. Perioperative complications were assessed according to the presence of major adverse cardiovascular events. Among the complications in the intra­ and postoperative period, myocardial infarction was observed in 5 (23%) patients who underwent revascularization of the lower extremity arteries (p < 0.001), which was accompanied by longer mechanical ventilation and higher doses of vasopressor and inotropic support in the intensive care unit. Problems associated with increased lower extremity ischemia were noted in 5 (19%) patients who underwent myocardial revascularization as the first step (p < 0.005). Conclusions. In the case of combined lesions of the coronary arteries and arteries of the lower extremities, coronary artery bypass grafting should always be performed first. If coronary pathology is not corrected, the risk of perioperative myocardial infarction, fatal arrhythmia, and death increases.

Open Access Just Published
Relevant
Abstract A030: Rapid extraction and detection of extracellular vesicle-derived PD-L1 in a microfluidic platform

Abstract Background. Extracellular vesicles (EV) are emerging as new biomarkers for cancer diagnostics and therapeutic monitoring1. For example, in patients that receive PD1/PD-L1 immune checkpoint inhibitors (a key pillar of cancer immunotherapy), circulating EV-derived PD-L1 is gaining attention as a non-invasive biomarker for therapeutic efficacy. Standard methodologies to measure EV-derived PD-L1 requires ultracentrifugation to first separate EVs and then quantify those that express PD-L1 using nano flow cytometry. These are tedious processes that require trained technologists in centralized facilities, which is a key barrier to frequently monitoring EV-based biomarkers. Yet, frequent monitoring is crucial to quickly identify and stop an ineffective therapy while more fruitful options are still available. Method. To bridge the gap, we develop a proof-of-concept digital microfluidic (DMF) device that can separate EVs directly from biofluids and quantify PD-L1+ EVs automatedly. Briefly, DMF device supports automatedly droplet handling, including droplet transport, splitting and mixing, based on electrowetting principles2. Immunomagnetic beads were used to capture EVs from biofluids, and EVs were then detected by electrochemical sensors inserted into the device. These tips of the electrochemical sensors were modified with gold nanoparticle self-assembled layers to enhance target binding, and CD9 antibodies were immobilized on the tips to bind to EVs. We then used anti-PD-L1 as secondary antibodies for target detection. Differential Pulse Voltammetry (DPV)3 were performed to obtain the results. Results. We used the DMF device to extract 109- 1011 #/mL EVs secreted by a human breast cancer cell line (MDA-MB-231). Briefly, 10 mL of cell culture media was loaded into the DMF device, and the sample was mixed and incubated with a 10 mL droplet of immunomagnetic beads to capture EVs. After 5 min, EVs were eluted in 20 mL of elution buffer, and the beads were discarded. We estimated the number of EVs using Nanoparticle Tracking Analysis; the number of EVs extracted on-chip was comparable with those that were extracted using standard in-tube method. We also verified the purity of the EVs extracted on-chip using Western Blot. Our results showed that the electrochemical sensors can detect as low as 104 #/mL PD-L1+ EVs, with a linear range of 104 – 107 #/mL (R2=0.9701). The entire process can be completed within 1 hour. Conclusion. We integrated automated EV extraction and their surface marker detection in a single DMF device. Our next step is to extract and detect EV-based biomarkers from plasma samples. This platform holds promise for the regular monitoring of EV-based biomarkers that are indicators of therapeutic responses in patients that receive cancer immunotherapies.

Just Published
Relevant
Evaluation of Capital Utilization Efficiency in Agricultural Listed Firms Based on a Three-Stage Data Envelopment Analysis

Rural revitalization is intricately tied to national prosperity, with listed companies in agriculture, forestry, animal husbandry, and fisheries playing pivotal roles in driving this transformative agenda. However, these sectors face critical challenges, notably resource constraints and environmental pressures, which underscore the necessity of evaluating capital utilization efficiency. This study employs a combined three-stage DEA model and Malmquist index to analyze capital utilization efficiency across 85 listed companies within China’s agriculture, forestry, animal husbandry, and fishery industries over the period 2018–2022. The primary objectives are to quantify capital utilization efficiency, identify pathways for industry optimization, advance ecological agricultural sustainability, and offer valuable insights to investors and policymakers. Key findings include: (1) When grouped by sub-sector and adjusted to account for external environmental factors and random disturbances, the initial comprehensive capital utilization efficiency in agricultural companies was found to be significantly overestimated. Subsequent third-stage adjustments revealed decreases in average comprehensive efficiency, technical efficiency, and scale efficiency by 29.79%, 3.03%, and 27.37%, respectively, largely driven by a marked decline in scale efficiency, ultimately diminishing overall efficiency. (2) The capital utilization efficiency in agricultural trading firms remains suboptimal, with scale efficiency posing a critical limitation. High dependency on government subsidies and excess specialized personnel further constrain efficiency improvements. (3) Dynamic analysis using the DEA-Malmquist model indicates low total factor productivity in the agricultural sub-sector, primarily due to inefficiencies in capital management and suboptimal scale allocation. These findings underscore the need for targeted strategies to enhance resource allocation and management, bolster talent development and financial management frameworks, and drive technological research and development, innovation, and efficient capital allocation across the agriculture, forestry, animal husbandry, and fishery sectors.

Just Published
Relevant
Isolation and Characterization of a Novel Escherichia Bacteriophage with Potential to Control Multidrug-Resistant Avian Pathogenic Escherichia coli and Biofilms

Background/Objectives: Avian pathogenic Escherichia coli (APEC) infection is a significant problem for the global chicken industry, as it decreases animal welfare and is associated with substantial economic losses. Traditionally, APEC infections have been controlled through the use of antibiotics, which has led to an increased prevalence of antibiotic-resistant E. coli. Therefore, developing alternative treatments for APEC infection is crucial. Methods: In this study, an Escherichia phage specific to multidrug-resistant (MDR) APEC, designated as phage vB_EcoP_PW8 (phage vECPW8), was isolated. The morphology, phage adsorption to host cells, one-step growth curve, thermal stability, pH stability, whole-genome sequencing, antibacterial ability, and antibiofilm efficacy of phage vECPW8 were evaluated. Results: The results demonstrated that phage vECPW8 has a Podoviridae morphology and is effective at lysing bacteria. Phage vECPW8 exhibited a high absorption rate to bacterial cells (more than 85% within 10 min) and had a latent period of 20 min, with a burst size of 143 plaque-forming units per cell. Additionally, phage vECPW8 showed good temperature and pH stability. The phage displayed strong antibacterial activity in vitro, and its efficacy in controlling bacteria was confirmed through scanning electron microscopy. Whole-genome sequencing revealed that the phage has a linear genome with 69,579 base pairs. The genome analysis supported the safety of the phage, as no toxin, virulence, or resistance-related genes were detected. Phage vECPW8 was identified as a novel lytic phage in the Gamaleyavirus genus and Schitoviridae family. The phage also demonstrated antibiofilm efficacy by reducing and preventing biofilm formation, as evidenced by biofilm biomass and bacterial cell viability measurements. Conclusions: These results indicate that phage vECPW8 is a promising candidate for the effective treatment of MDR APEC infections in poultry.

Open Access Just Published
Relevant